Black checkmark with a sparkle and a curved line underneath on a white background.
Company

INTELLIGENT BIO SOLUTIONS INC.

Ticker
INBS
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight the company's FDA submission progress, funding achievements, revenue growth, manufacturing partnerships, and regulatory certifications.

Recent developments:
  • Intelligent Bio Solutions submitted a 510(k) premarket notification to the FDA for its fingerprint-based drug screening system targeting codeine detection on September 9, 2026 [N1].
  • The company secured $5 million in funding as of September 1, 2026, to support its drug screening system nearing FDA filing [N2].
  • Q3 2026 revenue grew 46%, driven by rising demand for cartridges used in the drug screening system [N7].
  • The company completed final clinical studies and precision testing required for FDA submission in mid-2026 [N5][N6].
  • Intelligent Bio Solutions secured ISO recertification aligning with new FDA Quality Management System Regulation requirements in August 2026 [N4].
  • Manufacturing partnerships announced in early 2026 contributed to significant stock price rallies, including a 132.4% surge on January 2, 2026 [N8].
  • The company reported a widened Q2 loss with plans for FDA application submission by year-end 2026 [N3].
Overview

Intelligent Bio Solutions Inc. focuses on developing and commercializing non-invasive fingerprint-based drug screening systems. The company has advanced its product development through clinical studies and precision testing, culminating in a 510(k) FDA submission for codeine detection. It has secured funding and manufacturing partnerships to support commercialization efforts. The company operates with ongoing net losses and relies on equity financing to fund operations. It maintains ISO certification aligned with FDA quality standards and has reported significant revenue growth driven by cartridge sales.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Intelligent Bio Solutions Inc. is developing fingerprint-based drug screening technology and has recently submitted a 510(k) FDA premarket notification for its system detecting codeine. The company secured $5 million in funding to support FDA filing and operations. It reported 46% revenue growth in Q3 2026 driven by cartridge demand but continues to operate at a net loss with liquidity ratios indicating near-term operational funding needs. The company faces risks related to FDA clearance timing, capital raising, and Nasdaq listing compliance.

Scenarios for INBS

Bull case model:

The company has demonstrated operational progress with FDA submission, clinical study completions, and manufacturing partnerships that have driven revenue growth and investor interest. Its non-invasive fingerprint drug screening technology addresses a niche with potential demand in forensic and workplace testing markets. Securing FDA clearance could enable broader commercialization and market penetration.

Bear case model:

The company continues to operate at a net loss with negative cash flow and acknowledges material doubt about its ability to continue as a going concern without additional financing. FDA clearance is not guaranteed and may face delays or additional requirements. The company must maintain Nasdaq listing standards and manage dilution risks from outstanding warrants. Failure to raise capital on favorable terms could impair operations and growth prospects.

Moat:

The company's moat is based on its proprietary fingerprint-based drug screening technology, which offers a non-invasive alternative to traditional drug testing methods. Its progress toward FDA clearance and established manufacturing partnerships support potential market entry barriers. The ISO recertification aligning with FDA QMSR standards further strengthens its regulatory compliance position. However, the moat is contingent on successful regulatory approval and market adoption.

Risks overview
Risks summary
The most significant risks include uncertainty around FDA clearance timing and outcome, and the company's need to raise additional capital to sustain operations, which together pose material challenges to business continuity and growth.
Risks details:

• FDA Clearance Risk: The FDA 510(k) premarket notification for the fingerprint drug screening system may not be cleared on a timely basis or at all, which could delay or prevent commercialization in the U.S. market [N1][S2].
• Capital Raising and Liquidity Risk: The company has a history of net losses and negative cash flow, with material doubt about its ability to continue as a going concern beyond 12 months without additional financing. Failure to secure capital on favorable terms could impair operations [S2].
• Nasdaq Listing Compliance Risk: The company must maintain minimum bid price and other listing requirements on Nasdaq. Failure to comply could result in delisting, adversely affecting liquidity and investor confidence [S2].
• Dilution Risk: Outstanding warrants could cause substantial dilution to existing shareholders if exercised, potentially impacting stock price and shareholder value [S2].

FINAL FORECAST FOR INBS

Final take one line
Intelligent Bio Solutions exhibits high visibility through detailed regulatory progress, funding, and operational milestones amid ongoing financial and regulatory risks.
Final take 12 to 24 month view

Business trends: The company is advancing fingerprint-based drug screening technology with FDA submission and growing cartridge demand driving revenue growth.
Execution milestones: Completion of clinical studies, precision testing, ISO recertification, and securing manufacturing partnerships support commercialization efforts.
Key risks: FDA clearance uncertainty, capital raising challenges, Nasdaq listing compliance, and dilution risks from outstanding warrants.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Intelligent Bio Solutions Inc. develops and commercializes fingerprint-based drug screening systems.
  • The company submitted a 510(k) premarket notification to the FDA on September 9, 2026, seeking clearance for its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.
  • The FDA submission may face additional information requests or require new submissions, which could delay or affect clearance.
  • The company secured $5 million in funding as of September 1, 2026, to support operations and FDA filing activities.
  • Intelligent Bio Solutions posted 46% revenue growth in Q3 2026 driven by rising cartridge demand.
  • The company completed final clinical studies and precision testing for FDA submission in mid-2026.
  • It secured ISO recertification aligning with new FDA Quality Management System Regulation (QMSR) requirements in August 2026.
  • The company has entered manufacturing partnerships that have driven significant stock price rallies in early 2026.
  • As of September 30, 2026, the company had cash and cash equivalents of approximately $5.93 million and current assets of about $9.05 million, with current liabilities of approximately $4.58 million, resulting in a current ratio of 1.98 and a cash ratio of 1.3.
  • The company reported a net loss of approximately $2.66 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.86.
  • The company has outstanding warrants that could cause substantial dilution if exercised.
  • The company is listed on the Nasdaq Capital Market and must maintain listing requirements including a minimum bid price of $1.00 per share.
  • The company has experienced losses and negative cash flow from operations since inception and acknowledges material risk regarding its ability to continue as a going concern beyond 12 months without additional financing.
  • Executive compensation includes base salaries, bonuses tied to company and individual performance objectives related to liquidity, FDA submissions, and operational goals, and stock awards under a long-term incentive plan.
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-10-21 | 10-K/A
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-09-09 | www.nasdaq.com | Intelligent Bio Solutions Seeks FDA Clearance For Fingerprint-Based Drug Screening System | https://www.nasdaq.com/articles/intelligent-bio-solutions-seeks-fda-clearance-fingerprint-based-drug-screening-system
  • N2 | 2026-09-01 | www.nasdaq.com | Intelligent Bio Solutions Secures $5M Funding As Drug Screening System Nears FDA Filing | https://www.nasdaq.com/articles/intelligent-bio-solutions-secures-5m-funding-drug-screening-system-nears-fda-filing
  • N3 | 2026-08-19 | www.nasdaq.com | Intelligent Bio's Q2 Loss Widens As FDA Application Planned For Year-End; Stock Down | https://www.nasdaq.com/articles/intelligent-bios-q2-loss-widens-fda-application-planned-year-end-stock-down
  • N4 | 2026-08-18 | www.nasdaq.com | Intelligent Bio Solutions Secures ISO Recertification, Aligning With New FDA QMSR | https://www.nasdaq.com/articles/intelligent-bio-solutions-secures-iso-recertification-aligning-new-fda-qmsr
  • N5 | 2026-08-11 | www.nasdaq.com | Intelligent Bio Completes Final Clinical Study For FDA Clearance Of Codeine Screening System | https://www.nasdaq.com/articles/intelligent-bio-completes-final-clinical-study-fda-clearance-codeine-screening-system
  • N6 | 2026-07-22 | www.nasdaq.com | Intelligent Bio Solutions Completes Precision Testing For FDA Submission | https://www.nasdaq.com/articles/intelligent-bio-solutions-completes-precision-testing-fda-submission
  • N7 | 2026-05-13 | www.nasdaq.com | Intelligent Bio Solutions Posts 46% Q3 Revenue Growth, Driven By Rising Cartridge Demand; Stock Up | https://www.nasdaq.com/articles/intelligent-bio-solutions-posts-46-q3-revenue-growth-driven-rising-cartridge-demand-stock
  • N8 | 2026-01-02 | www.nasdaq.com | INBS Stock Surges 132.4% on New Manufacturing Partnership | https://www.nasdaq.com/articles/inbs-stock-surges-1324-new-manufacturing-partnership
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine